Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Jul 2013
celyad
Sole Global Coordinator & Joint Bookrunner
€ 26.4 million
Initial Public Offering

Cardio3

Cardio3 BioSciences is a Belgian biotechnology company aiming to heal heart failure

  • Cardio3 BioSciences floated on Euronext Brussels and Euronext Paris
  • Proceeds of the IPO were dedicated to fund European phase III trials of its flagship product, C-Cure
  • Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2023
Security
Privacy & cookies
Disclaimer